General Information,Business,Industry,Employees,Founded,Contact Information,Address,Phone Number,Web Address,View Prospectus,Financial Information,Market Cap,Revenues,Net Income,IPO Profile,Symbol,Exchange,Shares (millions),Price range,Est. $ Volume,Manager / Joint Managers,CO-Managers,Expected To Trade,Status,Quiet Period Expiration Date,Lock-Up Period Expiration Date,SCOOP Rating,Rating Change
General Information,"We intend to focus on industries that align well with the relationships and experience of our team and sponsor. We will seek to capitalize on the exceptional operating experience, capital markets expertise and vast network of our management team and advisors across the technology, media and telecommunications sectors.",BLANK CHECKS,0,2020,Contact Information,"14 Elm Place, Suite 206, Rye, New York 10580",(575) 914-6575,,890 5th Avenue Partners,Financial Information,$319.5mil,$0 mil (last 12 months),$0 mil (last 12 months),IPO Profile,ENFAU,NASDAQ,25.0,$10.00 - $10.00,$250.0 mil,Cowen/ Craig-Hallum Capital Group,-,1/12/2021,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
General Information,"We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Our lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of FGF21, is currently being developed for the treatment of NASH. NASH is a severe form of NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, HCC and death. There are currently no approved products for the treatment of NASH. FGF21 is a clinically-validated mechanism that has been shown in humans to reduce steatosis and address cardio-metabolic dysregulation.",PHARMACEUTICAL PREPARATIONS,14,2018,Contact Information,"535 Mission Street, 14th Floor, San Francisco, CA 94105, US",(415) 500-4614,http://www.89bio.com,89bio,Financial Information,$207.9mil,$0 mil (last 12 months),$-28.2 mil (last 12 months),IPO Profile,ETNB,NASDAQ,5.3,$16.00 - $16.00,$84.9 mil,BofA Merrill Lynch/ SVB Leerink/ RBC Capital Markets,Oppenheimer,11/11/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
General Information,"Our efforts to identify a prospective target business will not be limited to a particular industry or geographic location, although we currently intend to focus on opportunities in Asia. (Incorporated in the British Virgin Islands) (Note: 8i Acquisition 2 Corp. priced its SPAC IPO on Monday morning, Nov. 22, 2021, in line with the terms of its recently upsized terms in the prospectus: 7.5 million units at $10 each to raise $75 million. On Nov. 8, 2021, 8iAcquisition 2 Corp. increased the size of its SPAC IPO to 7.5 million units from 5 million units, its initial size, and kept the price at $10.)",BLANK CHECKS,0,2021,Contact Information,"c/o 6 Eu Tong Sen Street #08-13, Singapore 059817",+65-6788 0388,,8i Acquisition 2 Corp.,Financial Information,$671.9mil,$0 mil (last 12 months),$0 mil (last 12 months),IPO Profile,LAXXU,NASDAQ,7.5,$10.00 - $10.00,$75.0 mil,Maxim Group LLC,-,11/22/2021,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
General Information,"8i Enterprises Acquisition Corp is a British Virgin Islands business company incorporated as a blank check company for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although the Company intends to focus on operating businesses in Asia.",BLANK CHECKS,0,2019,Contact Information,"6 Eu Tong Sen Street, #08-13 The Central, Singapore 059817",+65 67880388,,8i Enterprises Acquisition,Financial Information,$64.7mil,$0 mil (last 12 months),$0 mil (last 12 months),IPO Profile,JFKKU,NASDAQ,5.0,$10.00 - $10.00,$50.0 mil,Chardan,-,3/28/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
